Squarepoint Ops LLC purchased a new stake in shares of Iqvia Holdings Inc (NYSE:IQV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 49,175 shares of the medical research company’s stock, valued at approximately $7,346,000.
A number of other institutional investors have also made changes to their positions in the stock. Commonwealth Equity Services LLC lifted its stake in Iqvia by 6.5% in the second quarter. Commonwealth Equity Services LLC now owns 11,742 shares of the medical research company’s stock valued at $1,889,000 after acquiring an additional 712 shares during the last quarter. Commerzbank Aktiengesellschaft FI increased its position in Iqvia by 15.0% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 6,862 shares of the medical research company’s stock worth $1,104,000 after buying an additional 894 shares during the last quarter. Greenleaf Trust increased its position in Iqvia by 4.0% during the second quarter. Greenleaf Trust now owns 1,802 shares of the medical research company’s stock worth $290,000 after buying an additional 70 shares during the last quarter. Brookstone Capital Management raised its holdings in Iqvia by 11.0% during the second quarter. Brookstone Capital Management now owns 4,180 shares of the medical research company’s stock valued at $673,000 after buying an additional 415 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in Iqvia by 29.3% during the second quarter. Arizona State Retirement System now owns 70,187 shares of the medical research company’s stock valued at $11,293,000 after buying an additional 15,904 shares in the last quarter. 90.06% of the stock is owned by hedge funds and other institutional investors.
IQV has been the subject of a number of analyst reports. ValuEngine cut Iqvia from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Wolfe Research raised Iqvia from a “peer perform” rating to an “outperform” rating in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $166.46.
Iqvia (NYSE:IQV) last released its earnings results on Wednesday, October 30th. The medical research company reported $1.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.57 by $0.03. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.76 billion. During the same quarter in the previous year, the business earned $1.42 EPS. The business’s revenue was up 6.7% on a year-over-year basis. Analysts anticipate that Iqvia Holdings Inc will post 5.9 earnings per share for the current year.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Story: What are Bollinger Bands?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.